Last edition
News about "Glomerular Filtration Rate"
Bayer's Finerenone Shows Kidney and Cardiovascular Benefits in Hypertensive CKD Subgroup
New FIND-CKD data highlight finerenone’s potential to slow kidney disease progression and reduce cardiovascular-kidney risks in patients with hypertensive nephropathy.
Glomerular Filtration Rate | 01/09/2026 | By News Bureau | 103
Bayer Files Japan Application to Expand Finerenone Use in Non-Diabetic CKD
Bayer’s Japan filing, backed by Phase III FIND-CKD data showing slower kidney function decline and a 23 percent reduction in cardiovascular-kidney events, seeks to expand finerenone’s potential role in treating adults with non-diabetic CKD and addressing a significant unmet medical need.
Glomerular Filtration Rate | 31/08/2026 | By News Bureau
Otsuka's Voyxact Meets Key Phase 3 Endpoint in IgA Nephropathy Study
Otsuka presented new Phase 3 VISIONARY trial findings showing that Voyxact significantly slowed kidney function decline over two years, reinforcing its potential as a disease-modifying therapy for adults with primary IgA nephropathy.
Glomerular Filtration Rate | 05/08/2026 | By News Bureau | 210
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy